<DOC>
	<DOCNO>NCT01698216</DOCNO>
	<brief_summary>The aim study observation effectiveness side effect patient schizophrenia switch antipsychotic risperidone long act injection paliperidone palmitate .</brief_summary>
	<brief_title>Switching From Consta® Sustenna® Patients With Schizophrenia</brief_title>
	<detailed_description>In study , investigator go enroll patient switch risperidone long act injection paliperidone palmitate . And investigator examine effectiveness side effect paliperidone palmitate . In addition , effectiveness side effect relate variable study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Age : 18 ~ 65 Patient schizophrenia accord DSMIV criterion Patient sign informed consent , well understood objective procedure study . Maintenance therapy 6 month Risperidone Long Acting Injection monotherapy concomitant antipsychotic , stable dose Risperidone Long Acting Injection maintain 8 week . The stable dose antipsychotic maintain 8 month . Patient want switch antipsychotic Paliperidone Palmitate . PANSS total score ≤ 80 Each score conceptual disorganization ( P2 ) , hallucinatory behavior ( P3 ) , Suspiciousness/persecution ( P6 ) , unusual thought content ( G9 ) PANSS ≤ 4 Competent patient manage answer questionnaire . In case female childbearing age , consent use appropriate contraceptive method ( oral pill , contraceptive injection , intrauterine device , double barrier method contraceptive patch ) entire duration study . No history antipsychotic use . Past history NMS . Allergy hypersensitivity Risperidone Paliperidone ER . Concomitant antipsychotic oral Risperidone Paliperidone ER . Initiating dosechanging SSRI , MAOI , TCA within 2 month ( maintenance allow stable least 30days prior study entry would dose change study ) Initiating Lithium , Valproic acid , Carbamazepine , Topiramate , Lamotrigine mood stabilizer within 2months ( maintenance allow ) . Patient suppose impossible participate study due clinical risk suicide aggressive behavior base clinician 's opinion . Current substance dependence ( DSMIV ) past history dependence ( 6months ) Significant biochemical hematological abnormality abnormal finding urinalysis , base clinician 's opinion . History cardiac disease predispose QT prolongation ( sick sinus , complete AV block , CHF , ventricular tachycardia , hypokalemia hypocalcemia ) current medication QT prolong drug Pregnant breastfeed female patient . History participate investigational drug trial within 1month prior screening . Investigator employee clinical trial center , personnel relate investigator trial center study , family employee investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Paliperidone</keyword>
	<keyword>Palmitate</keyword>
	<keyword>switch</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>subjective well-being</keyword>
</DOC>